V8 Peptides — Engineered Performance
Research Library
Semaglutide Development History: A Research Timeline
SemaglutideHistory

Semaglutide Development History: A Research Timeline

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is the development history of semaglutide? It runs through four steps: the discovery in 1983 that the proglucagon gene also encodes GLP-1 (Bell and colleagues), the isolation of the long-lived exendin-4 from Gila monster venom in 1992 (Eng and colleagues), the engineering of fatty-acid-acylated GLP-1 analogs that bind albumin and resist enzymatic breakdown, and the 2015 description of semaglutide itself (Lau and colleagues). This timeline follows the chemistry and the science, and leaves the clinical record to the clinical literature. For laboratory work, see the semaglutide product page. For laboratory research use only.

A history is useful to a researcher because each step solved a specific chemical problem, and each solution left a signature in the molecule. If you know that native GLP-1 is removed within minutes, the Aib residue, the arginine at position 34 and the fatty diacid stop looking arbitrary. This article assembles the timeline from primary papers, marks what each step contributed, and ends with what the history implies for handling a research vial today. The wider compound profile is in the semaglutide research overview.

Timeline at a glance

YearMilestoneWhy it matteredSource
1983Proglucagon cDNA sequence shows that the glucagon precursor also encodes glucagon-like sequencesIdentified the gene products that later became GLP-1 research targetsBell and colleagues
1992Exendin-4 isolated from Gila monster venomA GLP-1 receptor agonist with a natural resistance to rapid breakdownEng and colleagues
2006Review of the incretin system and receptor agonistsFramed GLP-1 receptor activation as a research and drug-development targetDrucker and Nauck
2007Physiology of GLP-1 reviewedConsolidated secretion, receptor distribution and actionsHolst
2015Semaglutide described, with its design rationaleCombined enzymatic stability and albumin binding in a single analogLau and colleagues
2019Development history of liraglutide and semaglutideTraced the lipidation strategy from first to second generationKnudsen and Lau

The table is deliberately short. Between these anchors lie dozens of structure–activity papers; the ones named here are those that fixed the main design decisions.

Before the molecule: finding GLP-1

The hormone was found by reading the gene. Bell and colleagues (1983) determined the sequence of a proglucagon-encoding clone and showed that the precursor contained, besides glucagon, two related sequences. One of them became known as glucagon-like peptide-1. The insight was that a single gene yields different peptides depending on how the precursor is processed in different tissues, which is why a pancreatic cell and an intestinal cell release different products. Holst (2007) later reviewed the physiology that followed: secretion of GLP-1 by intestinal cells after nutrient exposure, a receptor on pancreatic islets and other tissues, and rapid inactivation of the circulating peptide. That last property, a half-life measured in minutes, defined the engineering problem for everything that came after.

The detour through venom: exendin-4

Eng and colleagues (1992) isolated exendin-4 from the venom of the Gila monster and described it as an analog of exendin-3. Its sequence resembles GLP-1, it acts at the GLP-1 receptor, and it is more persistent in biological systems because the second residue is not recognized by the enzyme that inactivates GLP-1. The importance for the research record is conceptual. Exendin-4 proved that a stable agonist of the GLP-1 receptor could exist, and gave a natural example to compare with engineered ones. Drucker and Nauck (2006) reviewed the resulting generation of incretin-based agents and the contrasting strategies of resistance to degradation (modifying the N-terminus) and prolonged circulation (binding to larger proteins).

From native peptide to acylated analog

Two lessons from the early period shaped the design of semaglutide. First, the N-terminal alanine at position 8 of native GLP-1 is where the inactivating enzyme cuts, so replacing it with a residue that the enzyme does not accept, such as Aib, preserves receptor activation while blocking cleavage. Second, attaching a fatty acid to the peptide lets it bind albumin, which acts as a reservoir and slows renal clearance. Knudsen and Lau (2019) describe how this approach produced liraglutide first and then semaglutide, with a longer spacer, a diacid in place of a monoacid and further backbone changes in the second generation.

Design problemSolution in the analogConsequence for the laboratory
Enzymatic cleavage at the N-terminusAib at position 8Backbone persists in biological media; assay buffer composition still matters
Rapid clearanceFatty diacid side chain binding albuminPotency depends on albumin content of the medium
Need for one acylation siteArginine at position 34, single free lysineDefined product; mis-acylated forms are a recognizable impurity
Receptor engagement despite a bulky side chainHydrophilic spacer between peptide and lipidAmphiphilic molecule; adsorbs to plastic, foams on agitation

The 2015 description of semaglutide

Lau and colleagues (2015) report the discovery program that ended in semaglutide: the search among analogs with different side-chain lengths, linkers and backbone substitutions, the in vitro receptor data, the binding to albumin, and the pharmacokinetic behavior in animals. The paper is the origin of the structural description used today. The design lesson for a reader is that the final molecule was selected through a matrix of experiments, not from a single idea, so its properties are the net of several trade-offs. A change at one point (for example, lengthening the lipid) improves albumin binding but may affect potency or solubility, which is why the resulting molecule is sensitive to handling in ways that its simpler relatives are not.

What the history implies for handling today

Each historical solution has a practical corollary on the bench. Because the backbone resists the inactivating enzyme but not general degradation, solutions still age through deamidation, oxidation and aggregation. Because the molecule binds albumin, assay results depend on protein content. Because of the lipid, it adsorbs to surfaces, so low-binding plasticware, slow mixing and prompt use matter. The product page for the 10 mg vial lists lyophilized powder in a sealed clear glass research vial, storage at 2–8 °C or −20 °C for long-term holding, protection from heat, moisture and light, and the formula C187H291N45O59. Bench steps are in semaglutide reconstitution and handling, and the stability questions in semaglutide storage and stability. For the concentration arithmetic, use the reconstitution calculator.

Naming, brands and where to read further

The same molecule appears under a nonproprietary name, a chemical description and several commercial names, and it is the nonproprietary name that appears in the primary literature. The distinction between laboratory material and any marketed product is covered in semaglutide brand chemistry. Related reading includes what is sema (semaglutide) peptide, GLP-1 receptor agonists in research and semaglutide vs tirzepatide. Before relying on any vial, check the certificate in the COA library where one is published, and read how to read a COA. Other laboratory materials are in the shop.

Reading the history critically

Popular timelines often compress or reorder events, attribute the work to a single company or person, or blend preclinical, clinical and regulatory milestones into one narrative. Three habits guard against it. Date every claim to a primary paper. Separate chemistry milestones from clinical ones, since they answer different questions. And note when a claim comes from the organization that developed the molecule, which is not disqualifying but is context. The papers cited here are peer-reviewed and independently checkable by DOI.

How the timeline shaped later multi-receptor molecules

The acylation strategy did not stop at one receptor. Once a lipid side chain was shown to extend persistence without destroying receptor engagement, the same logic was applied to peptides that act at more than one receptor. Finan and colleagues (2013) described unimolecular dual incretins that combine activities in a single sequence, and later dual and triple agonists carry the same fatty-diacid design. For a laboratory this means that techniques validated on semaglutide, such as albumin-matched buffers, low-binding plasticware and native-ligand reference curves, transfer directly to its successors, while the interpretation changes because more than one receptor is engaged. The comparison between a single-receptor agonist and a multi-receptor one is developed in the library's incretin explainer and in the tirzepatide and retatrutide overviews.

It also means that quality questions repeat. Every acylated peptide is made by a multi-step process, every one has a characteristic impurity pattern, and every one benefits from the same analytical habits: read the chromatogram, confirm the mass and record the lot. History explains why those habits exist.

Open questions the history leaves for research

Several questions remain open at the level of basic research. How do differences in side-chain length and linker chemistry alter receptor bias across signalling outputs? How much of the albumin-binding effect is reproduced in the particular medium of a cell assay? Which degradation products of acylated peptides form under realistic laboratory storage, and do they retain receptor activity? Questions like these are answerable with ordinary tools, namely receptor-expressing cell lines, controlled buffers and chromatography with mass detection, and each would add to the record that the earlier papers started.

Frequently asked questions

When was GLP-1 discovered?

Its sequence was revealed in 1983, when Bell and colleagues showed that the proglucagon precursor contains glucagon-like sequences in addition to glucagon.

What is exendin-4?

A peptide isolated from Gila monster venom in 1992 that acts at the GLP-1 receptor and resists the enzyme that rapidly inactivates native GLP-1.

Why was native GLP-1 not used directly?

It is inactivated within minutes in biological fluids, so analogs were built that resist the enzyme and bind albumin.

Which came first, liraglutide or semaglutide?

Liraglutide. Semaglutide is described as a further development of the same acylation strategy, as set out in the development history by Knudsen and Lau.

What does the Aib residue do?

It hinders cleavage by dipeptidyl peptidase-4 at the N-terminus.

What does the fatty diacid do?

It binds albumin, which slows clearance and extends persistence.

When was semaglutide described in the literature?

In 2015, in the discovery paper by Lau and colleagues.

What formula does the V8 product page list?

C187H291N45O59, about 4,114 g/mol for the free peptide.

How is the vial stored?

At 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light, per the product page.

Does this article cover the clinical record?

No. It follows the chemistry and basic science; clinical history belongs in the clinical literature.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside the laboratory.

Related reading: Semaglutide Quality Standards: An Acceptance Checklist, Semaglutide Preclinical Animal Models: A Research Guide, Semaglutide Shelf Life: Designing a Stability Check.

References

  1. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302(5910):716-718. doi:10.1038/302716a0
  2. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992;267(11):7402-7405. doi:10.1016/S0021-9258(18)42531-8
  3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. doi:10.1016/S0140-6736(06)69705-5
  4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. doi:10.1152/physrev.00034.2006
  5. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
  6. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
  7. Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. doi:10.1126/scitranslmed.3007218

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.